Bibliographic Details
| Title: |
Pembrolizumab‐induced acquired perforating dermatosis |
| Authors: |
Yaron Gu, Dinuke deSilva, Christopher J. A. Henderson, Deshan F. Sebaratnam |
| Source: |
JEADV Clinical Practice, Vol 3, Iss 5, Pp 1611-1614 (2024) |
| Publisher Information: |
Wiley, 2024. |
| Publication Year: |
2024 |
| Collection: |
LCC:Dermatology
LCC:Diseases of the genitourinary system. Urology |
| Subject Terms: |
drug eruptions, immune checkpoint inhibitors, PD‐1 inhibitors, programmed cell death protein 1 inhibitor, Dermatology, RL1-803, Diseases of the genitourinary system. Urology, RC870-923 |
| More Details: |
Abstract Immune checkpoint inhibitors such as the programmed cell death‐1 (PD‐1) inhibitors, pembrolizumab and nivolumab, are frontline treatments for several types of solid‐organ malignancies. However, cutaneous adverse effects with PD‐1 inhibitor therapy are common and include lichenoid reactions, eczema, vitiligo and bullous dermatoses. Perforating dermatosis is a rare condition characterised by the extrusion of degenerate materials from the upper dermis through the epidermis and has rarely been reported in association with PD‐1 inhibitor therapy. Herein, we report the first case to our knowledge of acquired perforating dermatosis following treatment with pembrolizumab. |
| Document Type: |
article |
| File Description: |
electronic resource |
| Language: |
English |
| ISSN: |
2768-6566 |
| Relation: |
https://doaj.org/toc/2768-6566 |
| DOI: |
10.1002/jvc2.462 |
| Access URL: |
https://doaj.org/article/3cde5fcb94764132b3681a89de1d4f66 |
| Accession Number: |
edsdoj.3cde5fcb94764132b3681a89de1d4f66 |
| Database: |
Directory of Open Access Journals |
